澳大利亚Telix制药公司以250M美元收购美国RLS(美国)放射药剂网络公司,以扩大北美制造和分销。 Australian firm Telix Pharmaceuticals acquires US radiopharmacy network RLS (USA) Inc. for $250M to expand North American manufacturing and distribution.

一家澳大利亚公司Telix制药公司正在收购美国一家领先的放射药品网络RLS(美国)公司,以加强其北美制造和分销能力。 Telix Pharmaceuticals, an Australian firm, is acquiring RLS (USA) Inc., a leading U.S. radiopharmacy network, to enhance its North American manufacturing and distribution capabilities. 这一2.5亿美元的交易增加了31个有执照的药房和100 000多平方英尺的生产空间,使Telix能够部署其ARTMS QUANTM辐照系统,以高效生产放射性金属。 This $250 million deal adds 31 licensed pharmacies and over 100,000 square feet of production space, allowing Telix to deploy its ARTMS QUANTM Irradiation System for efficient radiometal production. 此举旨在加强供应链,扩大病人在美国市场中的准入。 The move aims to strengthen supply chains and broaden patient access across the U.S. market.